DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Ubicación actual:
> This Story

Forward Printable StoryPrint Comment




Rad Oncology Homepage

Xstrahl spotlights new RADiant treatment system at Texas Dermatology Society spring meeting

Proton Therapy Center in Prague becomes first Czech clinic to order RayStation

Apollo Proton Cancer Centre, Chennai performs India's first total marrow irradiation procedure

BC Cancer researchers demonstrate the promise of a novel radiation treatment for metastatic cancer patients

New trial seeks to reverse effects of dead brain tissue caused by radiation

Cyclotron for Varian ProBeam Compact installed at new treatment center in Singapore

Integrated Oncology Network and Gamma West announce transaction

AngioDynamics announces first patient enrolled in NanoKnife DIRECT clinical study for stage III pancreatic cancer treatment

Papua New Guinea hospital selects Varian's Halcyon radiotherapy system

LAP positions itself as a QA provider in radiation therapy

California Protons Cancer Therapy Center invites patients to enroll in breast cancer study and clinical trial

Press releases may be edited for formatting or style
SAN DIEGO--(BUSINESS WIRE)--California Protons Cancer Therapy Center today announced two major efforts representing significant steps forward in breast cancer treatment research involving its noninvasive, targeted proton therapy. Current California Protons patients as of Feb. 4, 2019, are invited to enroll in the Proton Collaborative Group (PCG) Registry of more than 13,000 patients. Separately, the PCG BRE007-12 Partial Breast Irradiation in early stage breast cancer clinical trial will enroll around five to eight females per year.

The PCG Registry has been in existence since 2010 and is a prospective tracking study that allows for the collection and analysis of patient information to evaluate the disease process and treatment-related outcomes, thus defining strengths and weaknesses of proton radiation therapy. Qualified patients are invited to enroll in person at their first physician visit during treatment.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

The primary objective of the PCG BRE007-12 Partial Breast Irradiation study is to determine freedom from ipsilateral breast recurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at three years post-treatment. One of the goals of this study is to determine whether or not limiting radiation to just a portion of the breast is as effective as the traditional treatment of the entire breast. A number of trials have suggested that this “partial breast” approach is every bit as effective as treating the entire breast and may also be less toxic. Performing such partial breast treatments with protons can help to further reduce toxicity by taking advantage of the protons’ ability to be precisely conformed to the target area without giving “spillover” radiation to surrounding healthy tissue such as the lung and heart.

PCG has partnered with 11 proton treatment centers in the U.S., and the data has been used in close to 50 scientific manuscripts, posters and academic presentations to date. PCG research has been presented at 20 medical conferences and has been published in a number of peer-reviewed medical journals.

Both the Patient Registry and the Partial Breast Irradiation Trial are Institutional Review Board (IRB)-approved. These breast cancer trials supplement California Protons Cancer Therapy Center’s ongoing research projects with the University of California San Diego (UCSD) and the Radiation Therapy Oncology Group (RTOG) Foundation 3510 Phase III randomized trial of proton versus photon therapy for patients with nonmetastatic breast cancer receiving comprehensive nodal radiation.

About California Protons Cancer Therapy Center
California Protons’ intensity-modulated pencil beam scanning technology is a highly precise form of cancer radiation treatment that enables doctors to selectively target tumors with high-dose radiation while sparing healthy tissue. California Protons’ pencil beam scanning technology precisely delivers proton radiation treatment within 2 millimeters and with the utmost care. The treatment attacks tumors layer by layer and minimizes harmful exposure to surrounding healthy tissue and organs. This is important for breast cancer patients who may face the risk of secondary cancers, lung injuries and major cardiac events later in life due to previous radiation exposure. The reduction of radiation-related toxicity also increases the likelihood that patients can complete treatment with fewer interruptions or delays.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019, Inc.